Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people starting Mounjaro experience some side effects, particularly in the first few weeks. The most common are gastrointestinal, including nausea, loose stools and reduced appetite, and they typically ease as your body adjusts. Mounjaro is a prescription-only medicine and a prescriber reviews your full health picture before it is ever dispensed. If you've been reading about the so-called 'skinny jab' and wondering what you're actually signing up for, this page walks through what the evidence and the NHS tirzepatide guidance show, clearly and without glossing anything over.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: it's a Tuesday morning, you've done your first injection, and by early afternoon your appetite has all but vanished. That is, for most people, the welcome part. The less welcome part is the wave of nausea that can come with it, and for some people, a day or two of loose stools or indigestion.
This is not a sign something has gone wrong. Tirzepatide, the active ingredient in Mounjaro, slows how quickly food leaves your stomach and acts on two gut-hormone receptors (GIP and GLP-1) involved in appetite regulation. That mechanism is precisely why it works for weight management, and it is also why the digestive system needs time to settle. The NHS tirzepatide page lists the most commonly reported effects as nausea, diarrhoea, vomiting, constipation, stomach pain, indigestion, burping, and feeling full quickly. Fatigue, headache and dizziness also appear in a smaller proportion of users.
If you want to understand more about the treatment itself before reading further about side effects, our Mounjaro treatment page explains how it works, who it is suitable for, and what the licensed dose schedule involves. The nausea most people experience is typically worst during those early weeks or after a dose step, then quietens, and our guide to Mounjaro jab side effects walks through what tends to happen at each stage in more detail. Eating smaller portions, avoiding very fatty or rich foods, and staying well hydrated are practical steps that many people find helpful, though your prescriber's specific advice always takes priority over general guidance.
For a fuller picture of how these effects vary across the dose range, the complete Mounjaro side effects guide covers the evidence in more depth.
Beyond the typical GI effects, there are side effects that are less common but more clinically significant. Knowing the difference matters.
Gallbladder problems, including gallstones, have been reported with tirzepatide in clinical trials. Symptoms to watch for include persistent pain in the upper right abdomen, sometimes with nausea or fever. This is worth mentioning to your prescriber if you have any history of gallbladder issues before starting treatment.
Hair thinning is reported by some people using GLP-1 medicines. The current understanding is that this is more likely related to rapid weight loss and the nutritional shift that accompanies it than to the medicine itself, but it is real and worth discussing with your prescriber if it concerns you. There is a separate page on Mounjaro and skin-related side effects if you want to read more on this.
Injection-site reactions, redness, itching or a small lump at the site, are common and generally mild. Rotating your injection site between the abdomen, thigh and upper arm helps reduce this.
Mood changes and thoughts of self-harm have been reported with GLP-1 medicines and are listed in the product information. These are not common, but they are serious. Tell your prescriber or GP immediately if you notice a significant change in your mood or mental state after starting Mounjaro.
Diabetic retinopathy changes have been reported in people with diabetes. If you notice any sudden change in your vision, seek medical advice promptly.
Some symptoms need same-day or emergency attention. Do not manage these at home or wait until your next scheduled appointment.
Severe, persistent abdominal pain that radiates towards your back, with or without vomiting, is the key symptom of acute pancreatitis. Following a January 2026 MHRA Drug Safety Update on GLP-1 medicines, pancreatitis is explicitly flagged as an infrequent but potentially serious risk. Stop taking Mounjaro and get urgent medical help if this happens.
Signs of a serious allergic reaction, including swelling of the face, lips or throat, difficulty breathing, or a widespread rash, require emergency care. Call 999.
Severe vomiting or diarrhoea lasting more than a day or two can cause dehydration significant enough to affect kidney function. If you cannot keep fluids down, seek medical advice; do not simply push through it.
Our clinical team at nume provides priority aftercare seven days a week, so if something does not feel right and you are unsure whether it is urgent, you can contact us directly rather than trying to work it out alone. That said, if you are in any doubt about a serious symptom, the NHS or emergency services always come first.
If you experience any suspected side effect, you can also report it to the MHRA's Yellow Card scheme. This helps regulators monitor how medicines perform in real-world use, and your report genuinely matters.
Deciding whether Mounjaro is right for you involves weighing these effects against your personal health context. That is a clinical conversation, not a checklist you fill in yourself. Our prescribers go through your health history, any other medicines you take and your specific circumstances before treatment is approved. The consultation is free, there is no pressure, and you get honest answers to questions like these.
One practical note: if you order before midday on a weekday, clinical review happens the same day, and if approved, your treatment goes out with DPD that afternoon. Some people find it reassuring to know their prescriber has read their notes properly before anything is dispatched, rather than it being an automated tick-box.
Mounjaro is a Black Triangle medicine (▼), meaning the MHRA requires additional monitoring while longer-term post-market data accumulates. That is standard for newer medicines, not a warning sign, but it does mean transparent reporting by patients matters more than usual. If you have questions about what to expect at a particular dose, people who are specifically curious about reactions at the injection site and the physical experience of each dose often find that the fat jab Mounjaro side effects page addresses their questions directly, while those wanting a broader overview of what users report across all weeks of treatment may prefer the Mounjaro jabs side effects page, and the general FAQs cover common concerns about starting treatment.
Ready to talk it through? Speak to our prescribers as part of a free consultation; they discuss suitability and side effects openly, so you start treatment with a clear picture of what to expect.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.